Compare Logitech International SA (LOGI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Novo Nordisk A/S — how do they compare? Logitech International SA trades at $104.61 (market cap $14.96B), while Novo Nordisk A/S trades at $45.99 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 13.9× Logitech International SA's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| LOGI | NVO | |
|---|---|---|
Market Cap | $14.96B | $207.85B |
Sector | Technology | Health |
52-Week High | $126.69 | $63.98 |
52-Week Low | $85.84 | $35.29 |
Enterprise Value | $13.30B | $222.55B |
Dividend Yield | 1.64% | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
